24.65
+0.18(+0.74%)
Currency In USD
| Previous Close | 24.47 |
| Open | 24.47 |
| Day High | 25.03 |
| Day Low | 24.33 |
| 52-Week High | 31.67 |
| 52-Week Low | 11.16 |
| Volume | 431,638 |
| Average Volume | 927,727 |
| Market Cap | 1.14B |
| PE | -11.47 |
| EPS | -2.15 |
| Moving Average 50 Days | 24.62 |
| Moving Average 200 Days | 19.72 |
| Change | 0.18 |
If you invested $1000 in Pacira BioSciences, Inc. (PCRX) 10 years ago, it would be worth $292.76 as of April 19, 2025 at a share price of $24.65. Whereas If you bought $1000 worth of Pacira BioSciences, Inc. (PCRX) shares 5 years ago, it would be worth $641.93 as of April 19, 2025 at a share price of $24.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
GlobeNewswire Inc.
Apr 17, 2025 9:00 PM GMT
-- $300 million aggregate share repurchase authorization-- -- Reinforces confidence in 5x30 plan – -- Continued focus on margin expansion and operational efficiency -- BRISBANE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (N
PharmaCorp Rx Inc. Announces Participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference
Newsfile
Apr 14, 2025 11:30 AM GMT
Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - PharmaCorp Rx Inc. (TSXV: PCRX) will be participating in the 2025 Bloom Burton & Co. Healthcare Investor Conference, which will take place on May 5 and 6 at the Metro Toronto Convention Centre.Dat
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
GlobeNewswire Inc.
Apr 07, 2025 8:30 PM GMT
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 -- -- Fresenius also licensed to sell generic bupivacaine liposome injectable susp
Data not available